Two measles, mumps, and rubella (MMR) vaccines are licensed in the US: M-M-R II (Merck & Co) and PRIORIX (GlaxoSmithKline Biologicals); these two vaccines are fully interchangeable in the schedule ...

A measles-mumps-rubella vaccine developed by GlaxoSmithKline was found to have immune response rates and a safety profile similar to the Merck vaccine, according to results from a phase 3 clinical ...

A phase II study of pemetrexed and pembrolizumab in patients (pts) with recurrent and/or metastatic (R/M) salivary gland cancer (SGC): Results from non-adenoid cystic cohort.. If you have the ...

RFK Jr supported the MMR vaccine’s efficacy in preventing measles, but also shared unproven treatment strategies.

The market is mainly driven by the sales of major human vaccines such as Prevnar 13, Gardasil, ProQuad, Varivax, M-M-R II, polio/pertussis/Hib vaccines, and influenza vaccines.

Survival outcomes of patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) treated with platinum-based chemotherapy plus paclitaxel after anti-PD-1 monotherapy.

One dose of MSD’s M-M-R II vaccine provides a 93% protection against measles. Credit: Jan Sonnenmair via Getty Images. ·Pharmaceutical Technology·Jan Sonnenmair via Getty Images.